Advanced Search

Journal of Traditional Chinese Medicine >

2022 , Vol. 42 >Issue 5: 788 - 794

DOI: https://doi.org/10.19852/j.cnki.jtcm.20220815.003

Research Articles

Network pharmacology and molecular docking study on the effect of Kaempferol in treatment of metabolic associated fatty liver disease

  • Kaixuan ZHOU ,
  • Dong ZHANG ,
  • Huiwei BAO ,
  • Lijing LI
Expand
  • College of Pharmacy, Changchun University of Chinese Medicine, Changchun 130117, China
LI Lijing, College of Pharmacy, Changchun University of Chinese Medicine, Changchun 130117, China. lilijing66@163.com Telephone: +86-16689574396

Received date: 2021-07-16

  Accepted date: 2021-10-26

  Online published: 2022-08-15

Supported by

Natural Science Foundation of Jilin Province: Study on the Pharmacodynamic Material Basis and Action Mechanism of Buyang Huanwu Decoction on Diabetic Glucolipid Metabolism Disorder Renal Injury Based on Metabolic Nuclear Receptor Pathway(YDZJ202201ZYTS199);National College Students Innovation and Entrepreneurship Training Program: Study on the Mechanism of Buyang Huanwu Decoction in the Treatment of Cardiovascular Complications of Diabetes(202210199020)

Fold

Abstract

OBJECTIVE: To study therapeutic effect of kaempferol on metabolic associated fatty liver disease (MAFLD) by network pharmacology and molecular docking combined with cell experiments.

METHODS: First, use the SwissTargetPrediction database to predict the targets of kaempferol, and collect the targets of MAFLD through the Disgenet database and the GeneCards database. Then, the common target of kaempferol and MAFLD was enriched and analyzed by the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes, and the protein-protein interaction (PPI) network was constructed through the string database to obtain the key targets, and carry out molecular docking of key targets with kaempferol; In cell experiment, oleic acid induced steatosis in HepG2 cells, which was intervened by kaempferol, the level of triglyceride (TG) was detected, the lipid deposition was observed by oil red O staining, and the protein expression was detected by Western blot.

RESULTS: The results showed that there are 33 common targets for kaempferol and MAFLD. The biological process of GO is related to the regulation of protein kinase B, cell apoptosis, inflammatory factors, lipoxygenase, etc. Its action pathway is related to the phosphatidylinositol-3-kinase and protein kinase B (PI3K-AKT) signaling pathway, hypoxia-inducible factor 1 signaling pathway, forkhead box protein O signaling pathway, AMP-activated protein kinase signaling pathway, tumor necrosis factor signaling pathway, etc., the key targets are protein kinase B (AKT1), pros-taglandin G/H synthase 2, matrix metalloproteinase-9, epidermal growth factor receptor, and the molecular docking of kaempferol with the four key targets shows good binding properties. Cell experiments show that kaempferol can reduce cell TG levels, reduce lipid deposition, increase the expression of PI3K, AKT, and beclin-1, and reduce the expression of caspase-3 and nuclear factor-kappa B. Kaempferol can treat MAFLD by regulating the PI3K-AKT signaling pathway to regulate cell autophagy, apoptosis, and inflammation.

CONCLUSIONS: This study shows that kaempferol can regulate lipid metabolism, reduce apoptosis, regulate inflammation and autophagy in the fatty liver cell model. It reveals the therapeutic mechanism of kaempferol on MAFLD and provides a natural product candidate for the treatment of MAFLD.

Key words： Metabolic associated fatty liver disease; kaempferol; network pharmacology; molecular docking simulation; protein kinase B; protoonco-gene proteins c-akt; signaling transduction

Cite this article

Kaixuan ZHOU , Dong ZHANG , Huiwei BAO , Lijing LI . Network pharmacology and molecular docking study on the effect of Kaempferol in treatment of metabolic associated fatty liver disease[J]. Journal of Traditional Chinese Medicine, 2022 , 42(5) : 788 -794 . DOI: 10.19852/j.cnki.jtcm.20220815.003

References

1. Jin L, Sun Y, Li Y, et al. A synthetic peptide AWRK 6 ameliorates metabolic associated fatty liver disease: involvement of lipid and glucose homeostasis. Peptides 2021; 143: 170597.
2. Nie H, Deng Y, Zheng C, et al. A network pharmacology-based approach to explore the effects of Chaihu Shugan powder on a non-alcoholic fatty liver rat model through nuclear receptors. J Cell Mol Med 2020; 24: 5168-84.
3. Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol 2021; 6: 578-88.
4. Hagström H, Kechagias S, Ekstedt M. Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease from the symposium: non-alcoholic fatty liver disease (NAFLD). J Intern Med 2021; 12: 13343.
5. Simental-Mendía LE, Gamboa-Gómez CI, Guerrero-Romero F, et al. Beneficial effects of plant-derived natural products on non-alcoholic fatty liver disease. Adv Exp Med Biol 2021; 1308: 257-72.
6. Xu L, Li Y, Dai Y, et al. Natural products for the treatment of type 2 diabetes mellitus: pharmacology and mechanisms. Pharmacol Res
7. Faghihzadeh F, Adibi P, Hekmatdoost A. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br J Nutr 2015; 114: 796-803.
8. Yang H, Yang T, Heng C, et al. Quercetin improves nonalcoholic fatty liver by ameliorating inflammation, oxidative stress, and lipid metabolism in db/db mice. Phytother Res 2019; 33: 3140-52.
9. Imran M, Salehi B, Sharifi-Rad J, et al. Kaempferol: a key emphasis to its anticancer potential. Molecules 2019; 24: 2277.
10. Zhou YP, Li GC. Kaempferol protects cell damage in in vitro ischemia reperfusion model in rat neuronal PC12 cells. Biomed Res Int 2020; 2020: 2461079.
11. Xiao Y, Liu L, Zheng Y, et al. Kaempferol attenuates the effects of XIST/miR-130a/STAT3 on inflammation and extracellular matrix degradation in osteoarthritis. Future Med Chem 2021; 13: 1451-64.
12. Gao J, Zhang M, Niu R, et al. The combination of cinnamaldehyde and kaempferol ameliorates glucose and lipid metabolism disorders by enhancing lipid metabolism via AMPK activation. J Funct Foods 2021; 83: 104556.
13. Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Nat Med 2013; 11: 110-20.
14. Csermely P, Korcsmáros T, Kiss HJ, et al. Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review. Pharmacol Ther 2013; 138: 333-408.
15. Law V, Knox C, Djoumbou Y, et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res 2014; 42: D1091-7.
16. Tsutsumi T, Eslam M, Kawaguchi T, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol Res 2021; 51(11): 1115-28.
17. Shi H, Tian S, Tian H. Network pharmacology interpretation of fuzheng-jiedu decoction against colorectal cancer. Evid-based Compl Alt 2021; 2021: 4652492.
18. Huang Q, Liu R, Liu J, et al. Integrated network pharmacology analysis and experimental validation to reveal the mechanism of anti-insulin resistance effects of moringa oleifera seeds. Drug Des Devel Ther 2020; 14: 4069-84.
19. Martinez JE, Kahana DD, Ghuman S, et al. Unhealthy lifestyle and gut dysbiosis: a better understanding of the effects of poor diet and nicotine on the intestinal microbiome. Front Endocrinol 2021; 12: 667066.
20. Tincopa MA, Wong J, Fetters M, et al. Patient disease knowledge, attitudes and behaviours related to non-alcoholic fatty liver disease: a qualitative study. BMJ Open Gastroenterol 2021; 8: e000634.
21. Li S, Qian Y, Xie R, et al. Exploring the protective effect of ShengMai-Yin and Ganmaidazao decoction combination against type 2 diabetes mellitus with nonalcoholic fatty liver disease by network pharmacology and validation in KKAy mice. J Ethnopharmacol 2019; 242: 112029.
22. Alkhalidy H, Moore W, Wang A, et al. Kaempferol ameliorates hyperglycemia through suppressing hepatic gluconeogenesis and enhancing hepatic insulin sensitivity in diet-induced obese mice. J Nutr Biochem 2018; 58: 90-101.
23. Varshney R, Varshney R, Mishra R, et al. Kaempferol alleviates palmitic acid-induced lipid stores, endoplasmic reticulum stress and pancreatic β-cell dysfunction through AMPK/mTOR-mediated lipophagy. J Nutr Biochem 2018; 57: 212-27.
24. Posor Y, Eichhorn-Grünig M, Haucke V. Phosphoinositides in endocytosis. Biochim Biophys Acta 2015; 1851: 794-804.
25. Hers I, Vincent EE, Tavaré JM. Akt signalling in health and disease. Cell Signal 2011; 23: 1515-27.
26. Fan H, Ma X, Lin P, et al. Scutellarin prevents nonalcoholic fatty liver disease (NAFLD) and hyperlipidemia via PI3K/AKT-dependent activation of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) in rats. Med Sci Monit 2017; 23: 5599-612.
27. Biancalana M, Natan E, Lenardo MJ, et al. NF-κB rel subunit exchange on a physiological timescale. Protein Sci 2021; 30: 1818-32.
28. He X, Wu J, Tan T, et al. Quassinoids from Brucea javanica and attenuates lipopolysaccharide-induced acute lung injury by inhibiting PI3K/Akt/NF-κB pathways. Fitoterapia 2021; 153: 104980.
29. Tutunchi H, Ostadrahimi A, Saghafi-Asl M, et al. Expression of NF-κB, IL-6, and IL-10 genes, body composition, and hepatic fibrosis in obese patients with NAFLD-Combined effects of oleoylethanolamide supplementation and calorie restriction: a triple-blind randomized controlled clinical trial. J Cell Physiol 2021; 236: 417-26.
30. Dludla PV, Nkambule BB, Mazibuko-Mbeje SE, et al. N-acetyl cysteine targets hepatic lipid accumulation to curb oxidative stress and inflammation in NAFLD: a comprehensive analysis of the literature. Antioxidants (Basel) 2020; 9: 1283.
31. Sun SC. The non-canonical NF-κB pathway in immunity and inflammation. Nat Rev Immunol 2017; 17: 545-58.
32. Ji G, Wang Y, Deng Y, et al. Resveratrol ameliorates hepatic steatosis and inflammation in methionine/choline-deficient diet-induced steatohepatitis through regulating autophagy. Lipids Health Dis 2015; 14: 134.
33. Singh R, Cuervo AM. Lipophagy: connecting autophagy and lipid metabolism. Int J Cell Biol 2012; 2012: 282041.
34. Ueno T, Komatsu M. Autophagy in the liver: functions in health and disease. Nat Rev Gastroenterol Hepatol 2017; 14: 170-84.
35. Levine B, Liu R, Dong X, et al. Beclin orthologs: integrative hubs of cell signaling, membrane trafficking, and physiology. Trends Cell Biol 2015; 25: 533-44.
36. Chu Q, Zhang S, Chen M, et al. Cherry anthocyanins regulate NAFLD by promoting autophagy pathway. Oxid Med Cell Longev 2019; 2019: 4825949.
Options
Outlines

/

〈 〉